联合灌注预防浅表性膀胱肿瘤术后复发的临床观察  

Clinical Study of Sequential Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Surgical Management

作　　者：陈忠[1] 李家贵[1] 叶章群[1] 杨为民[1] 张旭[1] 曾晓勇[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院泌尿外科,武汉430030

出　　处：《肿瘤防治研究》2005年第2期108-109,118,共3页Cancer Research on Prevention and Treatment

摘　　要：目的了解联合膀胱腔内灌注化疗方案对预防浅表性膀胱癌复发的疗效,探讨一种理想的膀胱腔内灌注方法.方法将45例(男性34例,女性11例)年龄在31～80岁(平均56.1岁)浅表性膀胱癌患者随机分为A、B和C 3组.A组接受单次表阿霉素灌注作为对照,B、C组接受不同的羟基喜树碱和丝裂霉素C序贯膀胱腔内灌注联合用药方案.结果A、B、C组平均随访时间分别为26.6月、36.73月、24.31月,复发率分别为54.5%(6/11)、27.7%(5/18)、6.25%(1/16).结论羟基喜树碱和丝裂霉素C合理地联合应用能取得较好疗效.Objective To determine the effect of sequential intravesical instillation to prevent superficial bladder cancer recurrence and seek ideal methods of intravesical instillation.Methods Four-five patients(34 men, 11 women) with superficial bladder cancer, mean age of 56.1 years(range 31～80), were randomly divided into three groups. A group received a single intravesical instillation of epirubicin as control, B group and C group received different sequential intravesical instillation of hydroxycamptothecine(HCPT) and mitomycin Cn(MMC) individually.Results The mean follow-up are (26.36) months, (36.73) months and 24.31 months for A, B, C groups. The recur rates are (54.5%)(6/11), (27.7%)(5/18), (6.25%)(1/16)individually. Conclusion The results showed that sequential intravesical with HCPT and MMC in reason maybe have better effects than a single intravesical instillation of epirubicin.

关 键 词：膀胱肿瘤 抗肿瘤药 多剂联用 多药耐药性 

分 类 号：R737.14[医药卫生—肿瘤] R979.1[医药卫生—临床医学]